The U.S. Court of Appeals for the Third Circuit has upheld a Pennsylvania federal judge’s dismissal of antitrust claims against GlaxoSmithKline over a patent infringement settlement with generic drugmakers allegedly aimed at delaying market entry of generic versions of the popular antidepressant Wellbutrin XL.

But the appeals court’s reasoning for upholding those rulings has not yet been revealed to the public. The court temporarily issued its Wednesday opinion under seal and, in a separate order, gave the parties until Aug. 15 to agree on proposed redactions.

According to the judgment, also issued Wednesday, a three-judge panel of the court—Judges Kent A. Jordan, Thomas I. Vanaskie and Richard L. Nygaard—affirmed two summary judgment rulings by U.S. District Judge Mary A. McLaughlin of the Eastern District of Pennsylvania from 2012 and 2015.

Stephen J. Kastenberg and Leslie E. John, of Ballard Spahr in Philadelphia, argued the case for GSK.

Read the full article here. Subscription may be required.


Related Practice